Description:
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
Sponsor:
Telix PharmaceuticalsContacts:
Jonathan Roger, MScjonathan.roger@telixpharma.com
579-366-1426 ext +1
Government Study Link:
NCT07197645 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
United States